Thus, when CrataBL binds to sulfated glycosaminoglycans in addition to interfering with the activity of kallikrein 7, which is important in melanoma [49], it may interfere with the activities of extracellular proteases which are indirectly inhibited by protecting the enzymes from glycosaminoglycans that are attached to the cell surface, impairing the potential of these compounds to enhance the activity of proteases. Here, KLK7 is linked to melanoma.